company background image
DIM

Sartorius Stedim Biotech ENXTPA:DIM Stock Report

Last Price

€314.10

Market Cap

€29.0b

7D

-6.3%

1Y

-39.3%

Updated

24 Sep, 2022

Data

Company Financials +
DIM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance5/6
Financial Health5/6
Dividends0/6

DIM Stock Overview

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide.

Sartorius Stedim Biotech Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sartorius Stedim Biotech
Historical stock prices
Current Share Price€314.10
52 Week High€544.00
52 Week Low€268.60
Beta0.47
1 Month Change-19.25%
3 Month Change2.88%
1 Year Change-39.34%
3 Year Change143.11%
5 Year Change436.01%
Change since IPO3,721.94%

Recent News & Updates

Jul 26
We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt

We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Jul 09
Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?

Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Jun 21
Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value

Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value

Does the June share price for Sartorius Stedim Biotech S.A. ( EPA:DIM ) reflect what it's really worth? Today, we will...

Shareholder Returns

DIMFR Life SciencesFR Market
7D-6.3%-7.1%-4.8%
1Y-39.3%-43.7%-14.1%

Return vs Industry: DIM exceeded the French Life Sciences industry which returned -45% over the past year.

Return vs Market: DIM underperformed the French Market which returned -14.1% over the past year.

Price Volatility

Is DIM's price volatile compared to industry and market?
DIM volatility
DIM Average Weekly Movement5.9%
Life Sciences Industry Average Movement7.1%
Market Average Movement4.8%
10% most volatile stocks in FR Market8.9%
10% least volatile stocks in FR Market2.7%

Stable Share Price: DIM is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: DIM's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
187011,942Joachim Kreuzburghttps://www.sartorius.com

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses.

Sartorius Stedim Biotech Fundamentals Summary

How do Sartorius Stedim Biotech's earnings and revenue compare to its market cap?
DIM fundamental statistics
Market Cap€28.95b
Earnings (TTM)€625.11m
Revenue (TTM)€3.26b

46.3x

P/E Ratio

8.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DIM income statement (TTM)
Revenue€3.26b
Cost of Revenue€1.54b
Gross Profit€1.72b
Other Expenses€1.09b
Earnings€625.11m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 19, 2022

Earnings per share (EPS)6.78
Gross Margin52.63%
Net Profit Margin19.18%
Debt/Equity Ratio30.6%

How did DIM perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

19%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is DIM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DIM?

Other financial metrics that can be useful for relative valuation.

DIM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.1x
Enterprise Value/EBITDA26.5x
PEG Ratio7.7x

Price to Earnings Ratio vs Peers

How does DIM's PE Ratio compare to its peers?

DIM PE Ratio vs Peers
The above table shows the PE ratio for DIM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average18.1x
ERF Eurofins Scientific
18.1x2.9%€11.7b
ALECR Eurofins-Cerep
10.5xn/a€102.9m
603259 WuXi AppTec
29.1x18.8%CN¥200.7b
SRT3 Sartorius
50.2x11.8%€23.2b
DIM Sartorius Stedim Biotech
46.3x6.0%€29.0b

Price-To-Earnings vs Peers: DIM is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the peer average (18.1x).


Price to Earnings Ratio vs Industry

How does DIM's PE Ratio compare vs other companies in the European Life Sciences Industry?

Price-To-Earnings vs Industry: DIM is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the European Life Sciences industry average (41x)


Price to Earnings Ratio vs Fair Ratio

What is DIM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DIM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.3x
Fair PE Ratio28.1x

Price-To-Earnings vs Fair Ratio: DIM is expensive based on its Price-To-Earnings Ratio (46.3x) compared to the estimated Fair Price-To-Earnings Ratio (28.1x).


Share Price vs Fair Value

What is the Fair Price of DIM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: DIM (€314.1) is trading above our estimate of fair value (€267.52)

Significantly Below Fair Value: DIM is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Sartorius Stedim Biotech forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


6.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIM's forecast earnings growth (6% per year) is above the savings rate (0.3%).

Earnings vs Market: DIM's earnings (6% per year) are forecast to grow slower than the French market (11.2% per year).

High Growth Earnings: DIM's earnings are forecast to grow, but not significantly.

Revenue vs Market: DIM's revenue (12.3% per year) is forecast to grow faster than the French market (5.3% per year).

High Growth Revenue: DIM's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DIM's Return on Equity is forecast to be high in 3 years time (25.2%)


Discover growth companies

Past Performance

How has Sartorius Stedim Biotech performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


28.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DIM has high quality earnings.

Growing Profit Margin: DIM's current net profit margins (19.2%) are lower than last year (19.6%).


Past Earnings Growth Analysis

Earnings Trend: DIM's earnings have grown significantly by 28.7% per year over the past 5 years.

Accelerating Growth: DIM's earnings growth over the past year (33.3%) exceeds its 5-year average (28.7% per year).

Earnings vs Industry: DIM earnings growth over the past year (33.3%) exceeded the Life Sciences industry 26.3%.


Return on Equity

High ROE: DIM's Return on Equity (29.3%) is considered high.


Discover strong past performing companies

Financial Health

How is Sartorius Stedim Biotech's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: DIM's short term assets (€1.7B) exceed its short term liabilities (€1.2B).

Long Term Liabilities: DIM's short term assets (€1.7B) exceed its long term liabilities (€1.1B).


Debt to Equity History and Analysis

Debt Level: DIM's net debt to equity ratio (23.3%) is considered satisfactory.

Reducing Debt: DIM's debt to equity ratio has increased from 22.6% to 30.6% over the past 5 years.

Debt Coverage: DIM's debt is well covered by operating cash flow (88.2%).

Interest Coverage: DIM earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Sartorius Stedim Biotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


0.40%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: DIM's dividend (0.4%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.99%).

High Dividend: DIM's dividend (0.4%) is low compared to the top 25% of dividend payers in the French market (5.93%).


Stability and Growth of Payments

Stable Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: DIM is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: DIM is not paying a notable dividend for the French market.


Cash Payout to Shareholders

Cash Flow Coverage: DIM is not paying a notable dividend for the French market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average board tenure


CEO

Joachim Kreuzburg (57 yo)

no data

Tenure

€2,004,000

Compensation

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH.Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengese...


CEO Compensation Analysis

Compensation vs Market: Joachim's total compensation ($USD1.95M) is below average for companies of similar size in the French market ($USD3.65M).

Compensation vs Earnings: Joachim's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: DIM's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 83.63% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
73.82%
Sartorius Aktiengesellschaft
68,044,513€21.4b0%no data
2.13%
FMR LLC
1,959,308€615.4m-4.43%0.05%
1.85%
BlackRock, Inc.
1,704,644€535.4m0.37%0.01%
0.98%
The Vanguard Group, Inc.
899,595€282.6m0.83%0.01%
0.56%
Norges Bank Investment Management
512,370€160.9m0%0.02%
0.46%
Baillie Gifford & Co.
419,756€131.8m1.77%0.06%
0.44%
Comgest S.A.
404,951€127.2m0.37%0.59%
0.43%
Invesco Ltd.
397,130€124.7m6.61%0.04%
0.31%
Rathbone Investment Management Limited
285,460€89.7m0.85%0.3%
0.29%
T. Rowe Price Group, Inc.
266,210€83.6m-0.08%0.01%
0.27%
Groupama Asset Management
247,267€77.7m0%1.38%
0.21%
Amundi Asset Management
189,384€59.5m1.24%0.02%
0.2%
DNCA Finance
188,301€59.1m-8.92%0.68%
0.2%
Natixis Investment Managers International
185,442€58.2m435.46%0.22%
0.17%
Geode Capital Management, LLC
154,977€48.7m-0.02%0.01%
0.16%
Capital Research and Management Company
145,963€45.8m-85.74%no data
0.16%
AllianceBernstein L.P.
143,725€45.1m-0.26%0.02%
0.15%
Premier Fund Managers Limited
141,315€44.4m13.03%0.48%
0.15%
CM-CIC Asset Management Société anonyme
133,840€42.0m0%0.73%
0.13%
Candriam Luxembourg S.A.
120,901€38.0m752.38%0.13%
0.13%
William Blair Investment Management, LLC
118,469€37.2m0.96%0.06%
0.12%
SEI Investments Company
110,083€34.6m76.37%0.05%
0.12%
Montanaro Asset Management Limited
106,948€33.6m0%2.31%
0.11%
Brown Brothers Harriman & Co., Asset Management Arm
104,127€32.7m0%0.22%
0.11%
Financiere De l'Echiquier
99,431€31.2m0%0.53%

Company Information

Sartorius Stedim Biotech S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sartorius Stedim Biotech S.A.
  • Ticker: DIM
  • Exchange: ENXTPA
  • Founded: 1870
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €28.953b
  • Shares outstanding: 92.18m
  • Website: https://www.sartorius.com

Number of Employees


Location

  • Sartorius Stedim Biotech S.A.
  • Zone Industrielle Les Paluds
  • Avenue de Jouques – CS 91051
  • Aubagne
  • Provence-Alpes-Côte d'Azur
  • 13781
  • France


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DIMENXTPA (Euronext Paris)YesShare CapitalFREURJul 2007
0RG8LSE (London Stock Exchange)YesShare CapitalGBEURJul 2007
56S1DB (Deutsche Boerse AG)YesShare CapitalDEEURJul 2007
SDMH.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJul 2007
DIMPBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBEURJul 2007
DIM NBMV (Bolsa Mexicana de Valores)YesShare CapitalMXMXNJul 2007
56S1ETLX (Eurotlx)YesShare CapitalITEURJul 2007
SRTO.YOTCPK (Pink Sheets LLC)UNSPONSRD ADSUSUSDDec 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/24 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.